FDA affirms five-year NCE exclusivity for Shire's Vyvanse
29 October 2009
Nancy Faigen
Please Login to read the full article.
29 October 2009
Nancy Faigen
Shire's attention deficit/hyperactivity disorder (ADHD) franchise has been given a lift now that the
US FDA has affirmed its earlier decision to grant five-year new chemical entity (NCE) exclusivity to Vyvanse (lisdexamfetamine dimesilate) following a challenge by a generic drug maker....
Please Login to read the full article.
RELATED CONTENT
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
